| Literature DB >> 31581552 |
Julia Langenau1, Heiner Boeing2, Manuela M Bergmann3, Ute Nöthlings4, Kolade Oluwagbemigun5.
Abstract
Alcohol consumption is an important lifestyle factor that is associated with several health conditions and a behavioral link with smoking is well established. Metabolic alterations after alcohol consumption have yet to be comprehensively investigated. We studied the association of alcohol consumption with metabolite patterns (MPs) among 2433 individuals from the European Prospective Investigation into Cancer and Nutrition (EPIC)-Potsdam Study, and a potential modification by smoking. Alcohol consumption was self-reported through dietary questionnaires and serum metabolites were measured by a targeted approach. The metabolites were summarized as MPs using the treelet transform analysis (TT). We fitted linear models with alcohol consumption continuously and in five categories. We stratified the continuously modelled alcohol consumption by smoking status. All models were adjusted for potential confounders. Among men, alcohol consumption was positively associated with six MPs and negatively associated with one MP. In women, alcohol consumption was inversely associated with one MP. Heavy consumers differed from other consumers with respect to the "Long and short chain acylcarnitines" MP. Our findings suggest that long and short chain acylcarnitines might play an important role in the adverse effects of heavy alcohol consumption on chronic diseases. The relations seem to depend on gender and smoking status.Entities:
Keywords: acylcarnitines; alcohol; amino acids; lipid metabolites; metabolite patterns; smoking; targeted metabolomics
Mesh:
Substances:
Year: 2019 PMID: 31581552 PMCID: PMC6836136 DOI: 10.3390/nu11102331
Source DB: PubMed Journal: Nutrients ISSN: 2072-6643 Impact factor: 5.717
Characteristics of the study population at the time of recruitment (1994–1998) in EPIC-Potsdam by gender.
| Number of Participants | Total | Men | Women | |
|---|---|---|---|---|
| 2433 | 934 | 1499 | ||
|
| ||||
| Age1, years | 50.46 (8.89) | 52.61 (7.87) | 49.13 (9.22) | <0.001 |
| BMI1, kg/m2 | 26.14 (4.33) | 26.80 (3.63) | 25.73 (4.68) | <0.001 |
| WC1, cm | 85.90 (12.87) | 94.18 (9.98) | 80.74 (11.73) | <0.001 |
| Education, university2 | 929 (38.2) | 490 (52.5) | 439 (29.3) | <0.001 |
| Full time employment (≥35 h/week)2 | 1435 (59.0) | 607 (65.0) | 828 (55.2) | <0.001 |
| Physically active, moderately inactive2a | 956 (39.3) | 348 (37.3) | 608 (40.6) | 0.157 |
| Alcohol consumption3 | 8.54 (3.01, 20.6) | 19.62 (8.92, 33.82) | 5.16 (2.02, 10.76) | <0.001 |
|
| <0.001 | |||
| Non-Consumersb | 72 (3.0) | 31 (3.3) | 41 (2.7) | |
| Lightc | 272 (11.2) | 61 (6.5) | 211 (14.0) | |
| Below recommended limitd | 1403 (57.7) | 479 (51.3) | 924 (61.6) | |
| Light to moderatee | 547 (22.5) | 296 (31.7) | 251 (16.7) | |
| Heavyf | 139 5.7) | 67 (7.2) | 72 (4.8) | |
|
| <0.001 | |||
| never smokerg | 1627 (66.9) | 553 (59.2) | 1074 (71.6) | |
| former smokerh | 352 (14.5) | 175 (18.7) | 177 (11.8) | |
| Current smoker | 454 (18.7) | 206 (22.1) | 248 (16.5) | |
|
| <0.001 | |||
| ≤ 15, CPD | 291 (64.1) | 102 (49.5) | 189 (76.2) | |
| 16–24, CPD | 112 (24.7) | 63 (30.6) | 49 (19.8) | |
| ≥ 25, CPD | 51 (11.2) | 41 (19.9) | 10 (4.0) | |
|
| ||||
| Cancer | 127 (5.2) | 30 (3.2) | 97 (6.5) | 0.001 |
| Stroke | 27 (1.1) | 18 (1.9) | 9 (0.6) | 0.005 |
| Myocardial infarction | 54 (2.2) | 42 (4.5) | 12 (0.8) | <0.001 |
|
| ||||
| Lipid-lowering Drugs | 130 (5.3) | 65 (6.9) | 65 (4.3) | 0.007 |
| Antiphlogistika | 5 (0.2) | 4 (0.4) | 1 (0.1) | 0.149 |
| Diuretics | 57 (2.3) | 21 (2.2) | 36 (2.4) | 0.916 |
Abbreviation: BMI, body mass index; cm, centimeter; CPD, cigarettes per day; kg, kilogram; m, meter; WC, waist circumstance; y, years; 1 Mean and standarddeviation in parentheses; 2 number and percentages; 3 median and interquartile range; a Cambridge physical activity index; b No consumption [no use of alcohol at enrolment/past 12 months]; c Light (>0 to ≤2 g/d (m); >0 to ≤1 g/d (w)); d below recommended limit (below RL) (>2 to ≤24 g/d (m); >1 to ≤12 g/d (w)); e light to moderate (>24 g/d to ≤60 g/d (m); >12 g/d to ≤30 g/d (w)); f heavy (>60 g/d (m); >30 g/d (w)); g Consisted of never smokers and ex-smoker who gave up smoking for ≥15years; h Ex-smoker who gave up smoking for ≤15 years.
Figure 1Associations between alcohol consumption in g/d and metabolite pattern scores at the time of recruitment (1994–1998) in EPIC-Potsdam; adjusted for age, sociodemographic and lifestyle factors, medications and chronic diseases-related medication. Changes in metabolite patterns scores with increased 12-g intake of alcohol per day in (a) men and (b) women; Abbreviation: AAs, SUG, ACs, Amino acids, sugar and free and short chain acylcarnitines, respectively; ACs I, Long and short chain acylcarnitines; ACs II, Medium and long chain acylcarnitines; ACs III, Short and medium chain acylcarnitines; acyl-alkyl, lysoPC, Acyl-alkyl- and lyso-phosphatidylcholine; diacyl, acyl-alkyl PCs, Diacyl- and acyl-alkyl-phosphatidylcholine; diacyl, acyl-alkyl, lysoPCs, SMs, Diacyl-, acyl-alkyl-, lyso- phosphatidylcholines and sphingomyelins.
Mean score differences of male participants at the time of recruitment (1994–1998) in EPIC-Potsdam in six metabolite patterns.
| Metabolite Patterns | Groups of Alcohol Consumers | Mean Score* |
|---|---|---|
| ACs I | Heavy | 0.952a |
| Light to moderate | 0.372b | |
| Below RL | −0.098c | |
| Light | −0.317c | |
| Non-consumers | −0.283c | |
| ACs II | Heavy | 0.715a |
| Light to moderate | 0.227ab | |
| Below RL | −0.106bc | |
| Light | −0.604c | |
| Non-consumers | −0.208bc | |
| SMs | Heavy | −0.240b |
| Light to moderate | 0.198ab | |
| Below RL | 0.261a | |
| Light | 0.066ab | |
| Non-consumers | 0.592a | |
| diacyl PCs | Heavy | 0.541a |
| Light to moderate | 0.228a | |
| Below RL | −0.008b | |
| Light | −0.015b | |
| Non-consumers | −0.183b | |
| diacyl PCs, acyl-alkyl PCs II | Heavy | 0.461a |
| Light to moderate | 0.254a | |
| Below RL | −0.009b | |
| Light | −0.194b | |
| Non-consumers | −0.581b |
Abbreviation: ACs I, Long and short chain acylcarnitines; ACs II, Medium and long chain acylcarnitines; diacyl PCs, Diacyl-phosphatidylcholines; diacyl PCs, acyl-alkyl PCs II, Diacyl-phosphatidylcholines and acyl-alkyl-phosphatidylcholine II; SMs, Sphingomyelins. Means followed by the same letter did not differ significantly (Tukey test, p > 0.05). Number of participants in each consumer group: non-consumers (n = 31), light (n = 61), below RL (n = 479), light to moderate (n = 269) and heavy consumers (n = 67); * mean of standard deviation score.
Linear regression models stratified by smoking status in men and women at the time of recruitment (1994–1998) in EPIC-Potsdam.
| Metabolite Patterns | Never Smoker | Former Smoker | Current Smoker | |||
|---|---|---|---|---|---|---|
|
| ||||||
| ACs I | 0.206 | <0.001 | 0.094 | 0.208 | 0.192 (0.072–0.312) | 0.002 |
| ACs II | 0.169 | <0.001 | 0.026 | 0.726 | 0.141 | 0.032 |
| diacyl PCs, acyl-alkyl PCs I | 0.097 | 0.021 | 0.013 | 0.877 | 0.037 | 0.523 |
| SMs | −0.035 | 0.308 | −0.057 | 0.430 | −0.137 | 0.020 |
| lysoPC | 0.043 | 0.030 | −0.029 | 0.525 | 0.075 | 0.014 |
| diacyl PCs | 0.127 | <0.001 | 0.082 | 0.100 | 0.119 | <0.001 |
| diacyl PCs, acyl-alkyl PCs II | 0.153 | <0.001 | 0.121 | 0.043 | 0.109 | 0.011 |
|
| ||||||
| acyl-alkyl, lysoPC | −0.068 | 0.104 | −0.127 | 0.289 | −0.184 | 0.043 |
Abbreviation: ACs I, Long and short chain acylcarnitines; ACs II, Medium and long chain acylcarnitines; acyl-alkyl, lysoPC, Acyl-alkyl- and lyso-phosphatidylcholine; diacyl PCs, Diacyl-phosphatidylcholines; diacyl, acyl-alkyl PCs I, Diacyl-glycerophosphocholines and acyl-alkyl-phosphatidylcholine I; diacyl PCs, acyl-alkyl PCs II, Diacyl-phosphatidylcholines and acyl-alkyl-phosphatidylcholine II; lysoPCs, Lyso-phosphatidylcholines; SMs, Sphingomyelins. 1 Men: never smoker, n = 553; former smoker, n = 175; current smoker n = 206. 2 Women: never smoker, n = 1074; former smoker, n = 177; current smoker, n = 248.